CTIS2022-500646-14-00招募中1 期
Immunotherapy in patients with early dMMR rectal cancer. A Danish DCCG phase II trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years., Has provided written informed consent prior to performance of any study procedure., Written informed consent must be obtained according to the local Ethics Committee requirements., Histologically verified non-metastatic rectal cancer stage 1-3., No indication for local therapy like TEM., Histologically verified dMMR or MSI., Performance status (WHO) of 0-1., No previous chemotherapy, radiotherapy or immunotherapy for colorectal cancer., Adequate haematological function defined as neutrophils ? 1.5 x 109/l and platelets = 100 x 109/l., Adequate organ function (bilirubin = 1.5 x UNL (upper normal limit), GFR (may be calculated) > 30 ml/min., Women of childbearing potential must have been tested negative in a serum pregnancy test within five days prior to registration. Fertile patients must agree to use a highly effective method of birth control. (i.e., pregnancy rate of less than 1 % per year) during the study and for six months after the discontinuation of study medication.
排除标准
- •Any other condition or therapy, which in the investigator’s opinion may pose a risk to the patient or interfere with the study objectives., Concomitant use of systemic glucocorticoids more than the equivalent dose to tablet prednisolone 10 mg/day. Treatment with systemic glucocorticoids must end no later than two weeks before inclusion., Subjects with active, known, or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol., Known allergy or intolerance to any of the drugs used (nivolumab and ipilimumab).
研究者
相似试验
招募中
2 期
Immunotherapy in Patients With Early dMMR Rectal CancerCancer of RectumNCT05732389Odense University Hospital39
招募中
1 期
Efficay of immunotherapy berfore surgery for localized dMMR colon cancerPatients with early stage (stage I-III) dMMR colon cancerMedDRA version: 21.0Level: LLTClassification code 10009951Term: Colon cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-006046-12-DKRigshospitalet85
招募中
不适用
Individualized therapy in patients with primary membranous nephropathyprimary membranous nephropathyNL-OMON28712Radboud UMC Nijmegen100
进行中（未招募）
不适用
Treatment of patients with locally advanced rectal cancer. TEGAFOX (UFT/leukovorin og Oxaliplatin) before, during and after curatively intended radiotherapy. A Danish phase I/II trial - TEGAFOXocally advanced non-resectable rectal cancerMedDRA version: 6.0Level: LLTClassification code 10038050EUCTR2004-001347-29-DKOdense University Hospital60
进行中（未招募）
1 期
Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE)Gastric, lower esophageal or GE-junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10015323 Term: Esophageal adenocarcinoma lower third stage unspecified System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10001150 Term: Adenocarcinoma gastric System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10030137 Term: Oesophageal adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLGT Classification code 10017991 Term: Gastrointestinal neoplasms malignant and unspecified System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000406-36-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)240